Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Oct 19;2005(4):CD002980.
doi: 10.1002/14651858.CD002980.pub3.

Acyclovir for treating varicella in otherwise healthy children and adolescents

T P Klassen  1 , L Hartling, N Wiebe, E M Belseck
Affiliations

Acyclovir for treating varicella in otherwise healthy children and adolescents

T P Klassen et al. Cochrane Database Syst Rev. .

Abstract

Background: Acyclovir has the potential to shorten the course of illness which may result in reduced costs and morbidity associated with chickenpox.

Objectives: 1) To examine the evidence evaluating the efficacy of acyclovir in alleviating symptoms of chickenpox and shortening the duration of illness. 2) To examine complications of chickenpox and adverse effects associated with acyclovir as reported in the relevant trials.

Search strategy: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 2, 2005), MEDLINE (January 1966 to June 2005), and EMBASE (1988 to June 2005). The reference lists of all relevant articles were reviewed. The primary author of relevant studies and the pharmaceutical company that manufactures acyclovir were contacted.

Selection criteria: Randomized controlled trials that evaluated otherwise healthy children zero to 18 years of age, with chickenpox.

Data collection and analysis: Two authors independently reviewed the studies for eligibility. Two authors independently assessed methodological quality of the relevant studies using the Jadad scale and allocation concealment. Differences were resolved by consensus. Data were extracted by one author using a structured form and checked by a second. Continuous data were converted to the weighted mean difference (WMD). Weighted mean differences were combined into an overall estimate using random effects. There were too few studies to consider exploring statistical heterogeneity between studies (i.e., differences in reported effects), formally, or to assess for publication bias.

Main results: Three studies were included. Study quality was three (n = 2) and four (n = 1) on the Jadad scale. Acyclovir was associated with a reduction in the number of days with fever (-1.1 days, 95% CI -1.3 to -0.9) and in reducing the maximum number of lesions (-76 lesions, -145 to -8). Results were less supportive with respect to the number of days to no new lesions and the number of days to the relief of itching. There were no clinically important differences between acyclovir and placebo with respect to complications associated with chickenpox or adverse effects associated with the treatment.

Authors' conclusions: Acyclovir appears to be effective in reducing the number of days with fever and the maximum number of lesions among otherwise healthy children with chickenpox. The results were less convincing with respect to the number of days to no new lesions and relief of itchiness. The clinical importance of acyclovir treatment in otherwise healthy children remains uncertain.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1.1
1.1. Analysis
Comparison 1 Acyclovir versus placebo, Outcome 1 Time to no new lesions.
1.2
1.2. Analysis
Comparison 1 Acyclovir versus placebo, Outcome 2 Maximum number of lesions.
1.3
1.3. Analysis
Comparison 1 Acyclovir versus placebo, Outcome 3 Time to no fever.
1.4
1.4. Analysis
Comparison 1 Acyclovir versus placebo, Outcome 4 Time to no itching.
1.5
1.5. Analysis
Comparison 1 Acyclovir versus placebo, Outcome 5 Skin complications.
1.6
1.6. Analysis
Comparison 1 Acyclovir versus placebo, Outcome 6 CNS complications.
1.7
1.7. Analysis
Comparison 1 Acyclovir versus placebo, Outcome 7 Respiratory complications.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

  • Acute cerebellitis in children: an eleven year retrospective multicentric study in Italy.
    Lancella L, Esposito S, Galli ML, Bozzola E, Labalestra V, Boccuzzi E, Krzysztofiak A, Cursi L, Gattinara GC, Mirante N, Buonsenso D, Tagliabue C, Castellazzi L, Montagnani C, Tersigni C, Valentini P, Capozza M, Pata D, Di Gangi M, Dones P, Garazzino S, Baroero L, Verrotti A, Melzi ML, Sacco M, Germano M, Greco F, Uga E, Crichiutti G, Villani A. Lancella L, et al. Ital J Pediatr. 2017 Jun 12;43(1):54. doi: 10.1186/s13052-017-0370-z. Ital J Pediatr. 2017. PMID: 28606112 Free PMC article.
  • Chickenpox.
    Breuer J, Fifer H. Breuer J, et al. BMJ Clin Evid. 2011 Apr 11;2011:0912. BMJ Clin Evid. 2011. PMID: 21486500 Free PMC article.
  • Antiviral agents for infectious mononucleosis (glandular fever).
    De Paor M, O'Brien K, Fahey T, Smith SM. De Paor M, et al. Cochrane Database Syst Rev. 2016 Dec 8;12(12):CD011487. doi: 10.1002/14651858.CD011487.pub2. Cochrane Database Syst Rev. 2016. PMID: 27933614 Free PMC article.
  • Management of varicella gangrenosa: a life-threatening condition from chickenpox.
    Schots JP, Moons P, Stoot JH. Schots JP, et al. Case Rep Med. 2014;2014:206152. doi: 10.1155/2014/206152. Epub 2014 Nov 19. Case Rep Med. 2014. PMID: 25505916 Free PMC article.
  • ORF7 of varicella-zoster virus is a neurotropic factor.
    Selariu A, Cheng T, Tang Q, Silver B, Yang L, Liu C, Ye X, Markus A, Goldstein RS, Cruz-Cosme RS, Lin Y, Wen L, Qian H, Han J, Dulal K, Huang Y, Li Y, Xia N, Zhu H. Selariu A, et al. J Virol. 2012 Aug;86(16):8614-24. doi: 10.1128/JVI.00128-12. Epub 2012 Jun 6. J Virol. 2012. PMID: 22674980 Free PMC article.
See all "Cited by" articles

References

References to studies included in this review

Balfour 1990 {published data only}
    1. Balfour HH Jr, Kelly JM, Suarez CS, Heussner RC, Englund JA, Crane DD, et al. Acyclovir treatment of varicella in otherwise healthy children. Journal of Pediatrics 1990;116(4):633‐9. - PubMed
    1. McGuirt PV, Clemmer A. Treatment of Chickenpox in Children with Acyclovir Suspension in a Double‐Blind Placebo‐Controlled Clinical Trial. Final Medical Report (Protocol ZOVIRAX 176). Available from: Burroughs Wellcome Co., Research Triangle Park, N.C. U.S.A 1988.
Balfour 1992 {published data only}
    1. Balfour HH Jr, Rotbart HA, Feldman S, Dunkle LM, Feder HM Jr, Prober CG, et al. Acyclovir treatment of varicella in otherwise healthy adolescents. Journal of Pediatrics 1992;120:627‐33. - PubMed
    1. McGuirt PV, Boone G, Harris J. Treatment of Chickenpox in Adolescents with AOVIRAZ Tablets in a Multicenter, Double‐Blind, Placebo‐Controlled Trial. Final Medical Report (Protocol ZOVIRAX 184). Available from: Burroughs Wellcome Co., Research Triangle Park, N.C. U.S.A 1990.
Dunkle 1991 {published data only}
    1. Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM Jr, Feldman S, et al. A controlled trial of acyclovir for chickenpox in normal children. New England Journal of Medicine 1991;325:1539‐44. - PubMed
    1. McGuirt PV, Boone G, Harris J. Treatment of Chickenpox in Children with ZOVIRAX Suspension in a Multicenter, Double‐Blind, Placebo‐Controlled Trial. Final Medical Report (Protocol ZOVIRAX 183). Available from: Burroughs Wellcome Co., Research Triangle, N.C. U.S.A 1990.

References to studies excluded from this review

Balfour 2001 {published data only}
    1. Balfour HH Jr, Edelman CK, Anderson RS, Reed NV, Slivken RM, Marmor LH, et al. Controlled trial of acyclovir for chickenpox evaluating time of initiation and duration of therapy and viral resistance. Pediatric Infectious Disease Journal 2001;20:919‐26. - PubMed
Feder 1990 {published data only}
    1. Feder HM. Treatment of adult chickenpox with oral acyclovir. Archives of Internal Medicine 1990;150:2061‐5. - PubMed
Huang 1995 {published data only}
    1. Huang Y‐C, Lin T‐Y, Chiu C‐H. Acyclovir prophylaxis of varicella after household exposure. Pediatric Infectious Disease Journal 1995;14:152‐4. - PubMed
Lin 1997 {published data only}
    1. Lin T‐Y, Huang Y‐C, Ning H‐C, Hsueh C. Oral acyclovir prophylaxis of varicella after intimate contact. Pediatric Infectious Disease Journal 1997;16:1162‐5. - PubMed
Suga 1993 {published data only}
    1. Suga S, Yoshikawa T, Ozaki T, Asano Y. Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella. Archives of Disease in Childhood 1993;69:639‐43. - PMC - PubMed

Additional references

Arvin 1987
    1. Arvin AM. Oral therapy with acyclovir in infants and children. Pediatric Infectious Disease Journal 1987;6:56‐8. - PubMed
Avery 1994
    1. Avery ME. Varicella‐zoster. In: Avery ME, First LR editor(s). Pediatric Medicine. 2nd Edition. Baltimore: Williams and Wilkins, 1989:1180‐1.
Balfour 1995
    1. Balfour HH. No reason not to treat. BMJ 1995;310:109‐10. - PMC - PubMed
Brunell 1987
    1. Brunell PA. Varicella‐zoster infections. In: Feign RD, Cherry JD editor(s). Textbook of pediatric infectious diseases. 2nd Edition. Philadelphia: WB Saunders, 1987:1602‐7.
Brunell 1991
    1. Brunell PA. Chickenpox‐examining our options. New England Journal of Medicine 1991;325(22):1577‐99. - PubMed
CDC 2001
    1. Centers for Disease Control and Prevention. Infectious diseases information: Varicella‐Zoster Virus. CDC: National Center for Infectious Diseases 2001 (www.cdc.gov/ncidod/diseases/list_varicl.htm).
Cole 1986
    1. Cole NL, Balfour HH Jr. Varicella‐zoster virus does not become more resistant to acyclovir during therapy. Journal of Infectious Diseases 1986;153:605‐8. - PubMed
Conway 1993
    1. Conway SP. Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella (commentary). Archives of Disease in Childhood 1993;69:642‐3. - PMC - PubMed
CPS 1999
    1. Canadian Paediatric Society (CPS). School and daycare exclusion policies for chickenpox: A rational approach. Infectious Diseases Immunization Committee, Canadian Paediatric Society. Paediatrics and Child Health 1999;4(4):287‐8. - PMC - PubMed
Croze 1994
    1. Croze SM, Stoukides CA. Oral acyclovir in immunocompetent patients with varicella. Annals of Pharmacotherapy 1994;28:208‐9. - PubMed
Drwal‐Klein 1993
    1. Drwal‐Klein LA, O'Donovan CA. Varicella in Pediatric Patients. Annals of Pharmocotherapy 1993;27(July/August):938‐49. - PubMed
Englund 1990
    1. Englund JA, Zimmerman ME, Swierkosz DM, Goodman JL, Schll DR, Balfour HH Jr. Acyclovir resistant herpex simplex virus: results from a tertiary care center. Annals of Internal Medicine 1990;112:416‐22. - PubMed
Feldhoff 1981
    1. Feldhoff CM, Balfour HH Jr, Simmons RL, Najarian JS, Mauer SM. Varicella in children with renal transplants. Journal of Pediatrics 1981;98:25‐31. - PubMed
Feldman 1975
    1. Feldman SF, Hughes WT, Daniel CB. Varicella in children with cancer: seventy‐seven cases. Pediatrics 1975;56:388‐97. - PubMed
Gershon 1975
    1. Gershon AA. Varicella in mother and infant: problems old and new. In: Krugman S, Gershon AA editor(s). Infections of the fetus and newborn infant. New York: Alan R. Liss, Inc, 1975:75‐95.
Ghirga 1992
    1. Ghirga G, Ghirga P, Pizzabiocca A, Maccarini I, Presti A. Treatment of varicella with low doses of acyclovir for two days (letter; comment). Journal of Pediatrics 1992;120(4 Part 1):664‐5. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1‐12. - PubMed
Laskin 1984
    1. Laskin OL. Acyclovir: pharmacology and clinical experience. Archives of Internal Medicine 1984;144:1241‐6. - PubMed
Lefebvre 2008
    1. Lefebvre C, Manheimer E, Glanville J. Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity‐ and precision‐ maximizing version (2008 revision); Ovid format. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chapter 6: Searching for studies. Chichester, UK: John Wiley & Sons, Ltd, 2008.
McKendrick 1995
    1. McKendrick MW. Acyclovir for childhood chickenpox. Cost is unjustified. BMJ 1995;310:108‐9. - PMC - PubMed
Meyers 1974
    1. Meyers JD. Congenital varicella in term infants; risk reconsidered. Journal of Infectious Diseases 1974;129:215‐7. - PubMed
Moore 1991
    1. Moore DA, Hopkins RS. Assessment of a school exclusion policy during a chickenpox outbreak. American Journal of Epidemiology 1991;133:1161‐7. - PubMed
Mouzard 1998
    1. Mouzard A. Traitement par antiviral de la varicelle du nourrisson et de l'enfant: les arguments contre. Medecine et maladies infectieuses 1998;28:832‐6.
Preblud 1981
    1. Preblud SR. Age‐specific risks of varicella complications. Pediatrics 1981;68(1):14‐7. - PubMed
Preblud 1984
    1. Preblud SR, Orenstein WA, Bart KJ. Varicella: clinical manifestations, epidemiology and health impact in children. Pediatric Infectious Diseases Journal 1984;3(6):505‐9. - PubMed
Preblud 1986
    1. Preblud SR. Varicella: Complications and costs. Pediatrics 1986;78(Suppl):728‐35. - PubMed
Ross 1962
    1. Ross AH. Modification of chickenpox in family contacts by administration of gamma globulin. New England Journal of Medicine 1962;267:369‐76. - PubMed
Rotbart 1993
    1. Rotbart HA, Levin MJ, Hayward AR. Immune responses to varicella zoster virus infections in healthy children. Journal of Infectious Diseases 1993;167:195‐9. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273:408‐12. - PubMed

References to other published versions of this review

Klassen 2002
    1. Klassen TP, Belseck EM, Wiebe N, Hartling L. Acyclovir for treating varicella in otherwise healthy children and adolescents: a systematic review of randomised controlled trials. BioMed Central Pediatrics 2002;2(1):9. - PMC - PubMed
Klassen 2004
    1. Klassen TP, Belseck EM, Wiebe N, Hartling L. Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD002980.pub3] - DOI - PubMed
Klassen 2005
    1. Klassen TP, Hartling L, Wiebe N, Belseck EM. Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD002980.pub3] - DOI - PMC - PubMed

Publication types